AB0410 Pregnancy and Anti-TNFα Drugs: Experience of Four Centres

BackgroundThe introduction of biologic therapies has significantly improved the outcome of inflammatory rheumatic diseases. As most of these diseases affect women and men in childbearing age there is concern about safety of biologic drugs during reproduction and pregnancy.ObjectivesTo evaluate the effects of anti-TNFα agents on pregnancy and foetal outcome.MethodsWe conducted a retrospective multicentre study of 24 women and 2 men with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA), respectively. They were treated with anti-TNFα agents prior to conception or until conception/during pregnancy. Data were collected from four Centres (Belluno, Padua, Trento and Udine). A 28-question chart abstraction form was filled by the treating rheumatologist. The primary outcome was the occurrence of congenital malformations. Secondary outcomes were the rate of premature birth (defined as